Home Drug IndexClinical Monograph

Budesonide Inhaled Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

Navigation

Therapeutic Class

Corticosteroid (Inhaled)

Subclass

Inhaled Glucocorticoid

Speciality

Pulmonology

Schedule (India)

Schedule H

Routes

Inhalation (Dry Powder Inhaler, Metered Dose Inhaler, Nebulisation)

Formulations

Dry Powder Inhaler (DPI): 100 mcg, 200 mcg, 400 mcg per actuation
Metered Dose Inhaler (MDI): 100 mcg, 200 mcg per actuation
Respules/Nebuliser Suspension: 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL (2 mL ampoule/respule)

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Bronchial Asthma — Maintenance Therapy

Adults and Adolescents (≥12 years) — Inhaler (DPI/MDI):

Mild Persistent Asthma:

Parameter	Recommendation
Starting dose	200–400 mcg/day in 1–2 divided doses
Titration	Increase by 200 mcg/day every 2–4 weeks if control inadequate
Usual maintenance dose	200–400 mcg/day
Maximum dose	800 mcg/day

Moderate Persistent Asthma:

Parameter	Recommendation
Starting dose	400–800 mcg/day in 2 divided doses
Titration	Adjust every 2–4 weeks based on symptom control
Usual maintenance dose	400–800 mcg/day
Maximum dose	1600 mcg/day

Severe Persistent Asthma:

Parameter	Recommendation
Starting dose	800–1600 mcg/day in 2 divided doses
Titration	Step-down by 25–50% every 3 months once asthma well-controlled
Usual maintenance dose	800–1200 mcg/day
Maximum dose	1600 mcg/day

Clinical Notes:

Administer via spacer device when using MDI to improve drug delivery
Rinse mouth with water after each use to prevent oropharyngeal candidiasis
Not a rescue medication — always ensure patient has access to SABA for acute symptoms
Onset of clinical effect may take 1–2 weeks; maximum benefit in 4–8 weeks

2. Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Therapy

Adults — In Combination with Long-Acting Bronchodilator (LABA):

Parameter	Recommendation
Starting dose	400 mcg twice daily (usually as FDC with formoterol)
Titration	Not applicable for ICS component; adjust based on exacerbation frequency
Usual maintenance dose	400–800 mcg/day in 2 divided doses
Maximum dose	800 mcg/day

Clinical Notes:

Indicated ONLY for COPD patients with frequent exacerbations (≥2/year or ≥1 hospitalisation) despite LABA/LAMA therapy
Typically prescribed as fixed-dose combination with formoterol (budesonide/formoterol)
Monotherapy with ICS NOT recommended in COPD
Consider blood eosinophil count >300 cells/μL as predictor of ICS response
Monitor for pneumonia risk with prolonged ICS use in COPD

3. Acute Asthma Exacerbation — Nebulised (Alternative to Systemic Steroids)

Adults:

Parameter	Recommendation
Starting dose	1–2 mg via nebuliser every 6–12 hours
Titration	Not applicable
Usual maintenance dose	1–2 mg twice daily
Maximum dose	4 mg/day
Duration	5–7 days

Clinical Notes:

May be used as alternative to oral prednisolone in mild-moderate exacerbations
Not a substitute for systemic corticosteroids in severe exacerbations
Can be mixed with nebulised bronchodilators (salbutamol, ipratropium) in same nebuliser chamber

Secondary Indications – Adults Only (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Eosinophilic Bronchitis — OFF-LABEL	400–800 mcg/day inhaled in 2 divided doses	4–8 weeks; reassess response	Specialist only (Pulmonology)	Small RCTs; Indian pulmonology practice
Allergic Bronchopulmonary Aspergillosis (ABPA) — as adjunct — OFF-LABEL	800–1600 mcg/day inhaled in 2 divided doses	Long-term with systemic steroids/antifungals	Specialist only	Limited evidence; tertiary centre practice

Paediatric indications''

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

1. Persistent Asthma — Maintenance Therapy

Age Restriction: May be used from 6 months of age via nebulisation. DPI/MDI use from age 5–6 years depending on technique.

Nebulised Budesonide (6 months – 5 years):

Severity	Starting Dose	Titration	Usual Maintenance	Maximum Dose
Mild persistent	0.25 mg once or twice daily	Increase to 0.5 mg BD if inadequate control	0.25–0.5 mg/day	1 mg/day
Moderate persistent	0.5 mg twice daily	Adjust based on symptom control	0.5–1 mg/day	1 mg/day
Severe persistent	0.5–1 mg twice daily	Step-down once controlled ≥3 months	1 mg/day	2 mg/day (short-term)

Inhaled Budesonide — DPI/MDI (6–11 years):

Severity	Starting Dose	Titration	Usual Maintenance	Maximum Dose
Mild persistent	100–200 mcg/day in 1–2 doses	Increase by 100 mcg every 2–4 weeks if needed	100–200 mcg/day	400 mcg/day
Moderate persistent	200–400 mcg/day in 2 doses	Adjust based on response	200–400 mcg/day	800 mcg/day
Severe persistent	400–800 mcg/day in 2 doses	Step-down once controlled	400–800 mcg/day	800 mcg/day

Adolescents (≥12 years):

Use adult dosing

Clinical Notes:

Use spacer device with MDI in all children
Nebulisation preferred in children <5 years or those unable to use inhaler correctly
Monitor height velocity every 6 months — growth suppression possible with high doses
Titrate to lowest effective dose once asthma controlled for ≥3 months

2. Acute Asthma Exacerbation — Nebulised

Children (≥6 months):

Parameter	Recommendation
Starting dose	0.5–1 mg via nebuliser every 12 hours
Titration	Not applicable
Usual dose	0.5–1 mg twice daily
Maximum dose	2 mg/day
Duration	3–7 days

Clinical Notes:

Effective alternative to oral prednisolone for mild-moderate exacerbations in children
Particularly useful when oral corticosteroid administration is difficult (vomiting, non-compliance)
May be combined with nebulised salbutamol

Secondary Indications – Paediatric (Off-label)

Indication	Age	Dose	Duration	Notes	Evidence Basis
Croup (Moderate-Severe Laryngotracheobronchitis) — OFF-LABEL	≥6 months	2 mg nebulised as single dose	Single dose; may repeat once after 30–60 minutes if needed	Emergency department setting; adjunct to dexamethasone	IAP guidelines; WHO; multiple RCTs
Viral-Induced Wheeze (Recurrent) — OFF-LABEL	≥12 months	0.5–1 mg nebulised twice daily during episodes	During acute episodes (3–7 days)	Specialist paediatric pulmonology supervision	Indian paediatric practice; limited RCT support

Minimum Age Statement:
Not recommended below 6 months of age except under specialist paediatric pulmonology supervision.

Safety Monitoring:

Height and weight at baseline and every 6 months
Assess inhaler/nebuliser technique at every visit
Monitor for oral candidiasis and dysphonia
Annual ophthalmologic assessment if on
high-dose ICS >1 year

Renal Adjustments

No dose adjustment required.

Budesonide undergoes extensive first-pass hepatic metabolism with minimal renal excretion. Renal impairment does not significantly affect systemic exposure from inhaled budesonide.

Hepatic adjustment

Severity	Recommendation
Mild impairment (Child-Pugh A)	No dose adjustment required
Moderate impairment (Child-Pugh B)	Use with caution; standard doses generally acceptable; monitor for systemic corticosteroid effects
Severe impairment (Child-Pugh C)	Use with caution; risk of increased systemic exposure; monitor for adrenal suppression; consider dose reduction if prolonged high-dose therapy

Note: Systemic absorption from inhaled route is low (~10–20%); hepatic impairment primarily affects oral budesonide formulations.

Contraindications

Known hypersensitivity to budesonide or any excipient (including lactose in DPI formulations)
Primary treatment of status asthmaticus or acute severe asthma attack requiring emergency intervention (ICS is not rescue therapy)
Active or quiescent pulmonary tuberculosis (unless on adequate anti-TB therapy)
Untreated systemic fungal, bacterial, or viral infections

Cautions

Active or latent pulmonary tuberculosis — may reactivate; ensure TB status assessed before initiating long-term ICS
Systemic fungal infections
Ocular herpes simplex
History of oropharyngeal candidiasis — emphasise mouth rinsing
Transferring from systemic corticosteroids — risk of adrenal insufficiency; taper systemic steroids gradually
Patients previously requiring oral corticosteroids for asthma — may have adrenal suppression
Prolonged high-dose use — risk of systemic effects (adrenal suppression, osteoporosis, cataracts, glaucoma)
Growth monitoring essential in children — may cause temporary reduction in growth velocity
Paradoxical bronchospasm — discontinue and use alternative if occurs
Pneumonia risk in COPD patients on ICS
Diabetes mellitus — may affect glycaemic control at high doses

Pregnancy

Parameter	Details
Risk category	Generally considered safe; extensive human data support use
Preferred status	Inhaled budesonide is the PREFERRED inhaled corticosteroid during pregnancy in India and internationally
When may be used	Should be continued in pregnant women with asthma; uncontrolled asthma poses greater risk to mother and fetus than ICS use
Monitoring	Monitor maternal asthma control (peak flow, symptoms); fetal growth monitoring as per routine antenatal care

Note: Poorly controlled asthma during pregnancy is associated with pre-eclampsia, preterm birth, and low birth weight — risks far outweigh theoretical concerns of ICS use.

Lactation

Parameter	Details
Compatibility	Compatible with breastfeeding
Drug levels in milk	Very low; minimal systemic absorption from inhaled route; estimated infant exposure <0.3% of maternal dose
Preferred status	Budesonide is the preferred ICS for breastfeeding mothers
Infant monitoring	No specific monitoring required; observe for general wellbeing, normal feeding pattern, and growth

Elderly

Parameter	Recommendation
Starting dose	Start at lower end of dosing range (200–400 mcg/day for asthma)
Titration	Titrate gradually based on response and tolerability
Special risks	Increased risk of osteoporosis, cataracts, glaucoma with prolonged high-dose use; monitor bone density if high-dose ICS >5 years; assess fall risk
Additional considerations	Higher prevalence of comorbidities (diabetes, osteoporosis); check inhaler technique — cognitive/motor impairment may affect use; consider nebulisation if inhaler technique poor

Major drug interactions

Drug/Class	Mechanism/Effect	Recommendation
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, posaconazole)	Marked increase in budesonide systemic exposure → risk of Cushing syndrome, adrenal suppression	Avoid combination if possible; if unavoidable, use lowest budesonide dose and monitor for systemic steroid effects
Ritonavir, cobicistat (potent CYP3A4 inhibitors)	Significant increase in budesonide exposure	Avoid inhaled budesonide in HIV patients on ritonavir-boosted regimens; consider alternative ICS (beclomethasone) or alternative antiretroviral
Systemic corticosteroids (prednisolone, dexamethasone)	Additive adrenal suppression risk	Use with caution; taper systemic steroids when initiating ICS; monitor for adrenal insufficiency

Moderate drug interactions

Drug/Class	Effect	Recommendation
Moderate CYP3A4 inhibitors (erythromycin, clarithromycin, diltiazem, verapamil, fluconazole)	Modest increase in budesonide systemic exposure	Monitor for systemic corticosteroid effects (Cushingoid features, hyperglycaemia); generally acceptable at standard inhaled doses
Grapefruit juice	Inhibits intestinal CYP3A4; minimal effect on inhaled route	No significant clinical interaction with inhaled budesonide
Live vaccines	Potential reduced immune response with high-dose prolonged ICS	Avoid live vaccines if on high-dose ICS (≥800 mcg/day) for >1 month; consult immunisation guidelines

Common Adverse effects

Oropharyngeal candidiasis (oral thrush)
Dysphonia (hoarseness of voice)
Throat irritation / pharyngitis
Cough after inhalation
Headache
Upper respiratory tract infection

Serious Adverse effects

Adverse Effect	Clinical Action
Paradoxical bronchospasm	Discontinue immediately; treat with SABA; switch to alternative ICS or delivery device
Adrenal suppression / Adrenal crisis	Risk with prolonged high-dose use or rapid withdrawal after transferring from systemic steroids; monitor for fatigue, hypotension; may require stress-dose steroids during illness/surgery
Hypersensitivity reactions (angioedema, urticaria, rash, bronchospasm)	Rare; discontinue and avoid future use
Growth retardation in children	Monitor height; use lowest effective dose; generally reversible effect
Posterior subcapsular cataracts / Glaucoma	Risk with prolonged high-dose use; periodic ophthalmologic examination recommended
Reduced bone mineral density / Osteoporosis	Risk with prolonged high-dose use (≥800 mcg/day for years); consider calcium/vitamin D supplementation and bone densitometry in at-risk patients
Pneumonia (in COPD patients)	Monitor for symptoms; higher risk with ICS in COPD than asthma

Monitoring requirements

Baseline:

Asthma/COPD severity assessment (symptom frequency, FEV1/peak flow if available)
Inhaler technique assessment
Height (mandatory in children)
Rule out active TB in endemic areas
Blood glucose if diabetic

After Initiation / Dose Change:

Reassess symptom control at 2–4 weeks
Review rescue inhaler use
Recheck inhaler technique
Assess for local adverse effects (oral thrush, dysphonia)

Long-term Monitoring:

Height velocity every 6 months in children
Symptom control and peak flow/spirometry at each visit
Annual review of step-down possibility
Ophthalmologic examination if on high-dose ICS >2 years
Bone mineral density if on high-dose ICS ≥5 years (especially elderly, postmenopausal women)
Screen for oral candidiasis
Periodic assessment of adrenal function if on high-dose ICS with systemic steroid history

Brands in India

Single-Ingredient Inhalers:

Budecort (Cipla) — DPI, MDI, Respules
Pulmicort (AstraZeneca) — DPI, Respules
Budesal (Lupin) — Respules
Budez (Sun Pharma) — DPI
Ribufort (Intas) — DPI

Fixed-Dose Combinations (FDCs) with Formoterol:

Foracort (Cipla) — DPI, MDI
Budamate (Lupin) — DPI
Symbicort (AstraZeneca) — DPI
Fomtide (Cipla) — DPI

Fixed-Dose Combinations with Salbutamol:

Aerocort (Cipla) — MDI

Fixed-Dose Combinations with Formoterol + Tiotropium (Triple Therapy):

Triohale (Cipla) — DPI

Price range (INR)

Formulation	Approximate Price
DPI 100 mcg (60–200 doses)	₹150–₹350 per inhaler
DPI 200 mcg (60–200 doses)	₹180–₹400 per inhaler
DPI 400 mcg (60 doses)	₹250–₹450 per inhaler
MDI 100 mcg (200 doses)	₹100–₹200 per inhaler
MDI 200 mcg (200 doses)	₹150–₹280 per inhaler
Respules 0.5 mg/mL (10 respules)	₹150–₹250 per pack
Respules 1 mg/mL (10 respules)	₹200–₹350 per pack

Included in NLEM 2022 (100 mcg, 200 mcg inhalers)
NPPA price ceiling applicable for scheduled strengths
Available through government supply for asthma/COPD programmes
Significant brand-to-brand price variation

Clinical pearls

Rinse mouth after every use — simple intervention dramatically reduces oral candidiasis and dysphonia; instruct all patients at initiation and reinforce at follow-up
Inhaler technique is critical — poor technique is the most common cause of apparent ICS failure; reassess technique at every visit; use spacer with MDI in all patients
Not a rescue medication — patients must understand that ICS is for prevention, not acute relief; always prescribe SABA (salbutamol) for breakthrough symptoms
Pregnancy-preferred ICS — budesonide has the most extensive safety data of all ICS during pregnancy; do not discontinue in pregnant asthmatics
Step-down when controlled — after 3 months of good asthma control, attempt to reduce ICS dose by 25–50%; maintain on lowest effective dose to minimise long-term risks
COPD requires justification — unlike asthma, ICS in COPD is reserved for frequent exacerbators with eosinophilic phenotype; avoid routine ICS in stable COPD without exacerbation history
Monitor growth in children — temporary reduction in growth velocity possible in first 1–2 years of ICS use; effect on final adult height is minimal (≤1 cm) with standard doses

Version

RxIndia v1.0 — 05 Jun 2025

Reference

- CDSCO approved product inserts
- Indian Pharmacopoeia
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- ICMR Guidelines on COPD Management
- IAP Guidelines on Childhood Asthma
- GINA Global Strategy for Asthma Management (supportive)
- GOLD COPD Guidelines (supportive)
- AIIMS Pulmonology Treatment Protocols
- WHO Model Formulary (paediatric dosing support)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.